Purna Pharmaceuticals Acquired by Ampersand Capital Partners — Healthcare M&A

Ampersand Capital Partners, a Boston-based private equity firm focused on growth investments in life sciences and healthcare, has acquired Purna Pharmaceuticals in an announced platform deal. Purna provides development and manufacturing services for liquid and semi-solid dosage forms for pharmaceutical industry customers. The transaction size was not disclosed. The acquisition is also positioned to expand Ampersand’s broader healthcare services footprint through a planned collaboration with MedPharm, its topical and transdermal pharmaceutical development and manufacturing platform.

Purna’s contract development and manufacturing capabilities support pharmaceutical companies seeking GxP-compliant production and formulation development across semi-solid and liquid formats. Ampersand’s strategy centers on building a trans-Atlantic service offering by combining Purna’s strengths with MedPharm’s topical and transdermal capabilities, aiming to serve global clients with a more integrated development-to-manufacturing workflow. The move highlights ongoing private equity interest in outsourced pharmaceutical services, where scale, quality systems, and customer relationships are key differentiators.

Deal terms beyond the acquisition structure were not provided, and no closing date was disclosed. Achelous Partners, LLC served as investment banking and financial advisor to Purna.